TransMedics Group, Inc. (TMDX)

US — Healthcare Sector
Peers: OPCH  GKOS  AKRO  OSCR  IMVT  KYMR  NAMS  INDV  HNGE  BRKR 

Automate Your Wheel Strategy on TMDX

With Tiblio's Option Bot, you can configure your own wheel strategy including TMDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TMDX
  • Rev/Share 16.6026
  • Book/Share 10.4126
  • PB 13.0034
  • Debt/Equity 1.4621
  • CurrentRatio 7.6893
  • ROIC 0.1084

 

  • MktCap 4627169431.0
  • FreeCF/Share 3.5367
  • PFCF 38.353
  • PE 50.3328
  • Debt/Assets 0.549
  • DivYield 0
  • ROE 0.3142

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade TMDX Needham Hold Buy -- $148 Oct. 23, 2025
Initiation TMDX Jefferies -- Buy -- $145 Oct. 13, 2025
Initiation TMDX Evercore ISI -- Outperform -- $155 Sept. 16, 2025
Initiation TMDX Stifel -- Hold -- $115 Sept. 4, 2025
Downgrade TMDX JP Morgan Overweight Neutral $116 $75 Dec. 17, 2024
Initiation TMDX Robert W. Baird -- Outperform -- $200 Sept. 24, 2024
Initiation TMDX Needham -- Buy -- $208 Aug. 21, 2024

News

TMDX INVESTOR REPORT: TransMedics Group, Inc. is being Investigated for Securities Fraud - Contact BFA Law if you Suffered Losses
TMDX
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ:TMDX) for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc.

Read More
image for news TMDX INVESTOR REPORT: TransMedics Group, Inc. is being Investigated for Securities Fraud - Contact BFA Law if you Suffered Losses
TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking – Hagens Berman
TMDX
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a damaging report by activist short-seller Scorpion Capital. TransMedics' stock price has dropped $9.84, or 13%, since Scorpion released a report, titled “Walk Like An Egyptian,” leveling serious allegations against the company, including fraud, organ trafficking, and off-label device misuse.

Read More
image for news TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking – Hagens Berman
The Schall Law Firm Invites Investors With Losses In TransMedics Group, Inc. To Join A Securities Fraud Investigation
TMDX
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral

LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Read More
image for news The Schall Law Firm Invites Investors With Losses In TransMedics Group, Inc. To Join A Securities Fraud Investigation

About TransMedics Group, Inc. (TMDX)

  • IPO Date 2019-05-02
  • Website https://www.transmedics.com
  • Industry Medical - Devices
  • CEO Waleed H. Hassanein
  • Employees 728

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.